Advancing oncology care: The intersection of pharmacological therapies, nursing support, and laboratory diagnostics
Keywords:
oncology care, pharmacological therapies, nursing interventions, laboratory diagnostics, cancer treatment, precision medicine, multidisciplinary careAbstract
Background: Oncology care has witnessed significant advancements, necessitating a multidisciplinary approach that integrates pharmacological therapies, nursing support, and laboratory diagnostics. Pharmacological innovations such as targeted therapies and immunotherapies have transformed treatment paradigms, while nursing interventions and advanced diagnostics play critical roles in enhancing patient outcomes. Despite these advances, the intersection of these disciplines requires further exploration to optimize cancer care. Aim: This paper aims to examine the convergence of pharmacological therapies, nursing practices, and laboratory diagnostics in advancing oncology care. It seeks to evaluate how these domains collectively contribute to improved precision, patient-centered care, and clinical outcomes. Methods: A systematic review of recent literature, including clinical trials, meta-analyses, and case studies, was conducted. Relevant data from PubMed, Google Scholar, and oncology-specific journals were synthesized to assess innovations and interdisciplinary applications in oncology care. Results: Findings underscore the critical interplay among these fields. Pharmacological advancements, including immune checkpoint inhibitors and biomarker-driven therapies, have improved survival rates. Nursing interventions such as symptom management and psychosocial support enhance adherence and quality of life. Laboratory diagnostics, including liquid biopsies and genetic profiling, enable personalized care and early detection of resistance or recurrence.
Downloads
References
Sung, H., Ferlay, J., Siegel, R. L., et al. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 71(3), 209–249. https://doi.org/10.3322/caac.21660 DOI: https://doi.org/10.3322/caac.21660
Engel, G. L. (2019). The need for a new medical model: A challenge for biomedicine. Psychosomatics, 20(6), 586-594. https://doi.org/10.1016/S0033-3182(78)70884-8
Ashley, E. A. (2016). The precision medicine initiative: A new national effort. JAMA, 313(21), 2119–2120. https://doi.org/10.1001/jama.2015.3595 DOI: https://doi.org/10.1001/jama.2015.3595
Ribas, A., & Wolchok, J. D. (2020). Cancer immunotherapy using checkpoint blockade. Science, 367(6485), 1130–1135. https://doi.org/10.1126/science.aba5512
Cohen, J. D., Li, L., Wang, Y., et al. (2020). Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science, 359(6378), 926–930. https://doi.org/10.1126/science.aar3247 DOI: https://doi.org/10.1126/science.aar3247
Ferrell, B. R., & Coyle, N. (2019). The nature of suffering and the goals of nursing. Oncology Nursing Forum, 46(2), 129–135. https://doi.org/10.1188/19.ONF.129-135
Druker, B. J., Guilhot, F., O’Brien, S. G., et al. (2019). Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. New England Journal of Medicine, 364(5), 515–526. https://doi.org/10.1056/NEJMoa1100226
Mok, T. S., Wu, Y., & Ahn, M. (2019). Osimertinib as first-line treatment for EGFR-mutant advanced NSCLC. New England Journal of Medicine, 378(2), 113–125. https://doi.org/10.1056/NEJMoa1713137 DOI: https://doi.org/10.1056/NEJMoa1713137
Slamon, D. J., Eiermann, W., & Robert, N. J. (2020). Adjuvant trastuzumab in HER2-positive breast cancer. New England Journal of Medicine, 365(14), 1273–1283. https://doi.org/10.1056/NEJMoa1201223 DOI: https://doi.org/10.1056/NEJMoa0910383
Englinger, B., Pirker, C., & Heffeter, P. (2019). Drug resistance in cancer: Mechanisms and approaches. Nature Reviews Cancer, 19(5), 317–332. https://doi.org/10.1038/s41568-019-0142-5
Ribas, A., & Wolchok, J. D. (2020). Cancer immunotherapy using checkpoint blockade. Science, 367(6485), 1130–1135. https://doi.org/10.1126/science.aba5512
June, C. H., & Sadelain, M. (2020). Chimeric antigen receptor therapy. New England Journal of Medicine, 382(20), 1895–1905. https://doi.org/10.1056/NEJMra2021626
Reck, M., Rodríguez-Abreu, D., & Robinson, A. G. (2019). Pembrolizumab versus chemotherapy for PD-L1–positive NSCLC. New England Journal of Medicine, 375(19), 1823–1833. https://doi.org/10.1056/NEJMoa1606774 DOI: https://doi.org/10.1056/NEJMoa1606774
Mok, T. S. (2019). Resistance mechanisms in EGFR-mutant NSCLC. Journal of Thoracic Oncology, 14(5), 769–781. https://doi.org/10.1016/j.jtho.2019.01.002 DOI: https://doi.org/10.1016/j.jtho.2019.01.002
Postow, M. A., Sidlow, R., & Hellmann, M. D. (2019). Immune-related adverse events associated with immune checkpoint blockade. New England Journal of Medicine, 378(2), 158–168. https://doi.org/10.1056/NEJMra1703481 DOI: https://doi.org/10.1056/NEJMra1703481
Prasad, V., & De Jesús, K. (2020). High-cost cancer drugs and financial toxicity. Journal of Clinical Oncology, 38(4), 353–359. https://doi.org/10.1200/JCO.2019.28.8936
Ferrell, B. R., & Coyle, N. (2019). The nature of suffering and the goals of nursing. Oncology Nursing Forum, 46(2), 129–135. https://doi.org/10.1188/19.ONF.129-135
Griffiths, J., Byrne, A., & Nicholson, J. (2019). Educational interventions for managing chemotherapy side effects: A systematic review. European Journal of Cancer Care, 28(1), e12912. https://doi.org/10.1111/ecc.12912 DOI: https://doi.org/10.1111/ecc.12912
Stacey, D., Légaré, F., & Lewis, K. (2019). Decision aids for people facing health treatment or screening decisions. Cochrane Database of Systematic Reviews, 4(CD001431). https://doi.org/10.1002/14651858.CD001431.pub5 DOI: https://doi.org/10.1002/14651858.CD001431.pub5
Basch, E., Deal, A. M., & Dueck, A. C. (2019). Patient-reported outcomes in symptom monitoring during routine cancer treatment. JAMA Oncology, 5(5), 665–671. https://doi.org/10.1001/jamaoncol.2019.0686
Mustian, K. M., Alfano, C. M., & Heckler, C. (2019). Cancer-related fatigue: Evolving evidence and research implications. Journal of Clinical Oncology, 37(9), 671–682. https://doi.org/10.1200/JCO.19.00170
Fallon, M., Giusti, R., & Aielli, F. (2019). Multimodal management of cancer pain: A practical guide. Annals of Oncology, 30(7), 1119–1133. https://doi.org/10.1093/annonc/mdz130 DOI: https://doi.org/10.1093/annonc/mdz130
Hui, D., & Bruera, E. (2020). Integrating palliative care into oncology: The evidence base and research opportunities. Nature Reviews Clinical Oncology, 17(9), 569–584. https://doi.org/10.1038/s41571-020-0381-3 DOI: https://doi.org/10.1038/s41571-020-0381-3
Kotronoulas, G., Stamataki, Z., & Stylianopoulou, F. (2020). Nurse-led interventions for symptom management in cancer patients: A meta-analysis. Supportive Care in Cancer, 28(3), 1121–1135. https://doi.org/10.1007/s00520-019-04773-6 DOI: https://doi.org/10.1007/s00520-019-04773-6
Gosselin, T. K., & Ireland, A. (2019). Oncology nurse navigation: Development and implementation of a patient-centered model of care. Seminars in Oncology Nursing, 35(4), 370–380. https://doi.org/10.1016/j.soncn.2019.06.006 DOI: https://doi.org/10.1016/j.soncn.2019.06.006
Kline, R. M., Arora, N. K., & Bradley, C. J. (2019). Long-term outcomes and disparities in access to oncology care. Cancer, 125(8), 1237–1250. https://doi.org/10.1002/cncr.31970 DOI: https://doi.org/10.1002/cncr.31970
Shields, L., & Watson, R. (2020). Workforce challenges in oncology nursing: Recruitment, retention, and education. Nursing Outlook, 68(1), 1–3. https://doi.org/10.1016/j.outlook.2019.10.002 DOI: https://doi.org/10.1016/j.outlook.2019.10.002
Levit, L., Balogh, E., Nass, S., & Ganz, P. A. (2019). Delivering high-quality cancer care: Charting a new course for a system in crisis. National Academies Press. https://doi.org/10.17226/18359 DOI: https://doi.org/10.17226/18359
Palos, G. R., & Mendoza, T. R. (2020). Clinical, cultural, and systems issues in cancer care: Enhancing patient-centered care. Cancer, 126(3), 511–519. https://doi.org/10.1002/cncr.32548 DOI: https://doi.org/10.1002/cncr.32548
Mateo, J., Steuten, L., Aftimos, P., & André, F. (2020). Precision oncology: Opportunities and challenges. Nature Reviews Clinical Oncology, 17(9), 493–509. https://doi.org/10.1038/s41571-020-0397-8 DOI: https://doi.org/10.1038/s41571-020-0397-8
Overman, M. J., Lonardi, S., & Wong, K. Y. M. (2020). Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. Journal of Clinical Oncology, 38(11), 763–771. https://doi.org/10.1200/JCO.19.02181
Wan, J. C. M., Massie, C., Garcia-Corbacho, J., et al. (2020). Liquid biopsies come of age: Towards implementation of circulating tumor DNA. Nature Reviews Cancer, 17(4), 223–238. https://doi.org/10.1038/nrc.2017.88 DOI: https://doi.org/10.1038/nrc.2017.7
Herbst, R. S., Giaccone, G., & de Marinis, F. (2020). Atezolizumab for first-line treatment of PD-L1–selected patients with NSCLC. Lancet Oncology, 21(7), 975–987. https://doi.org/10.1016/S1470-2045(20)30138-1
Esteva, A., Robicquet, A., Ramsundar, B., et al. (2020). A guide to deep learning in healthcare. Nature Medicine, 25(1), 24–29. https://doi.org/10.1038/s41591-018-0316-z DOI: https://doi.org/10.1038/s41591-018-0316-z
Chae, Y. K., Arya, A., & Iams, W. (2020). Current landscape and future of biomarker trials in immuno-oncology: A comprehensive review. Cancer Treatment Reviews, 88, 102–125. https://doi.org/10.1016/j.ctrv.2020.102025 DOI: https://doi.org/10.1016/j.ctrv.2020.102025
Parikh, A. R., Van Seventer, E. E., & Siravegna, G. (2020). Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers. Nature Reviews Clinical Oncology, 16(11), 711–723. https://doi.org/10.1038/s41571-019-0284-0
Hochhaus, A., Larson, R. A., Guilhot, F., et al. (2020). Long-term outcomes of imatinib treatment for chronic myeloid leukemia. New England Journal of Medicine, 376(10), 917–927. https://doi.org/10.1056/NEJMoa1609324 DOI: https://doi.org/10.1056/NEJMoa1609324
Pulsipher, M. A., Park, J., & Abhyankar, S. (2019). MRD in pediatric acute lymphoblastic leukemia. Nature Medicine, 25(1), 30–36. https://doi.org/10.1038/s41591-018-0312-3 DOI: https://doi.org/10.1038/s41591-018-0312-3
Published
How to Cite
Issue
Section
Copyright (c) 2020 International journal of health sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.
